Soquelitinib Overview - Soquelitinib is a first-in-class immune modulator with broad potential in cancer and immune diseases, targeting ITK [4, 5] - It has a novel mechanism of action with opportunities in oncology and immune diseases [5] - The drug has demonstrated a convenient oral dosing and attractive safety/tolerability profile in over 100 patients [5] - Corvus has strong IP protection with issued composition patents extending to November 2037 [5] Clinical Trials and Data - A randomized Phase 3 trial in PTCL is enrolling, with the potential for the first fully FDA-approved drug for PTCL [23, 24] - Phase 1 study in atopic dermatitis (AD) showed a significant reduction in EASI score at 28 days of treatment [68] - In the AD study, the 200 mg BID dose showed earlier and deeper responses, along with greater reductions in itch [68] - In AD Cohorts 1 and 2 (N=24), the mean EASI change was a 54.6% reduction, while in Cohort 3 (N=12), it was a 64.8% reduction, compared to a 34.4% reduction in the combined placebo group (N=12) [42] - In AD Cohort 3, 50% of patients with baseline PP-NRS ≥4 experienced a ≥ 4-point decrease in PP-NRS at Day 28 [53] Market and Future Development - The atopic dermatitis (AD) market is projected to reach $28 billion by 2030 [34] - Angel Pharma initiated a Phase 1b/2 trial in China for atopic dermatitis in Q4 2025 [59, 62] - Corvus anticipates data from the atopic dermatitis Phase 1 extension cohort 4 in January 2026 and plans to initiate a Phase 2 trial in early Q1 2026 [58, 69]